Filing Analysis
Insight Molecular Diagnostics Inc. announced its Q2 2026 financial results and disclosed that it received an Additional Information Request (AIR) from the FDA regarding its GraftAssureDx submission.
🚩 Red Flags
- Regulatory delay: The FDA's AIR indicates that the current submission for GraftAssureDx was insufficient to grant immediate clearance/approval, creating a timeline risk.
📋 Key Facts
- Company released financial results for the three and six months ended June 30, 2026.
- The FDA issued an Additional Information Request (AIR) concerning the GraftAssureDx submission.
- The Company has 180 days to provide a complete response to the FDA's AIR.
- Management expects one additional meeting with the FDA before Q4 2026.
Insight Molecular Diagnostics Inc. reported the results of its 2026 Annual Meeting of Shareholders held on June 11, 2026. Shareholders elected four directors, ratified the appointment of CBIZ CPAs P.C. as independent auditors, approved executive compensation, and approved an expansion of the company's equity incentive plan.
📋 Key Facts
- Annual Meeting held on June 11, 2026, with 74.19% of voting power represented.
- Shareholders approved an increase of 1,750,000 shares to the Amended and Restated 2018 Equity Incentive Plan, bringing the total authorized shares under the plan to 5,550,000.
- Elected directors for the 2027 term: Joshua Riggs, Andrew Arno, Andrew J. Last, and Louis E. Silverman.
- CBIZ CPAs P.C. was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Executive compensation for the year ended December 31, 2025, was approved on a non-binding advisory basis.
Insight Molecular Diagnostics Inc. filed an 8-K/A to amend a previous filing, correctly reclassifying the announcement of a Specimen Collection Agreement with Quest Diagnostics from Item 1.01 to Item 8.01. The agreement pertains to specimen collection services for the Company's GraftAssureCore™ dd-cfDNA blood test.
📋 Key Facts
- The company entered into a Specimen Collection Agreement with Quest Diagnostics.
- The agreement supports the GraftAssureCore™ test, a PCR-based measurement platform for donor-derived cell free DNA (dd-cfDNA).
- This filing is an amendment (8-K/A) dated May 13, 2026, correcting a filing from February 20, 2026.
Insight Molecular Diagnostics Inc. (IMDX) announced its financial results for the first quarter ended March 31, 2026. The announcement was made via a press release furnished as an exhibit to the filing.
📋 Key Facts
- Financial results cover the three-month period ended March 31, 2026
- The report was filed on May 13, 2026
- Information was furnished under Item 2.02 and is not deemed 'filed' for Section 18 liability purposes
- The company is listed on The Nasdaq Stock Market LLC under the ticker IMDX
Insight Molecular Diagnostics Inc. filed this 8-K to correct a clerical error in its Third Amended and Restated Bylaws previously filed with its 2025 Annual Report. The original exhibit inadvertently included incorrect shareholder voting provisions that were not part of the actual bylaws.
🚩 Red Flags
- Clerical error in a primary governing document (Bylaws) suggests potential lapses in administrative oversight or legal review of SEC filings.
📋 Key Facts
- The company filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, on March 26, 2026.
- Exhibit 3.5 of the 10-K contained a clerical error regarding shareholder voting provisions.
- The company is filing the corrected Third Amended and Restated Bylaws as Exhibit 3.1 to this 8-K.
- The correction does not change any other disclosures contained in the previously filed Form 10-K.
Insight Molecular Diagnostics Inc. (IMDX) furnished its financial results for the quarter and fiscal year ended December 31, 2025, via a press release on March 26, 2026.
📋 Key Facts
- Announced financial results for the "three and twelve months ended December 31, 2025"
- Press release furnished as Exhibit 99.1
- Reported on March 26, 2026, under Item 2.02 Results of Operations and Financial Condition
Insight Molecular Diagnostics Inc. (IMDX) entered into a Specimen Collection Agreement with Quest Diagnostics for its GraftAssureCore™ blood test. The agreement includes a provision for both parties to negotiate in good faith for additional rights to the GraftAssure technology.
📋 Key Facts
- Agreement entered on February 20, 2026, with Quest Diagnostics Incorporated.
- Quest will provide specimen collection services for IMDX's GraftAssureCore™ test, which measures donor-derived cell free DNA (dd-cfDNA).
- IMDX will pay fees to Quest for services rendered.
- The parties agreed to a specified period to negotiate additional rights to the GraftAssure technology.
- The full text of the agreement was not included but is expected in a future filing.
Insight Molecular Diagnostics Inc. completed a registered direct offering of common stock and pre-funded warrants to institutional investors. The offering raised approximately $24.5 million in net proceeds intended for R&D expansion into heart transplant rejection testing.
🚩 Red Flags
- Dilution risk due to the issuance of over 3.4 million new shares and significant warrant overhang.
- Pre-funded warrants with near-zero exercise prices ($0.0001) act as delayed equity dilution.
📋 Key Facts
- Offering size: 3,482,498 shares of common stock and up to 1,043,478 pre-funded warrant shares.
- Pricing: $5.75 per share; Pre-Funded Warrants priced at $5.7499 (effectively $0.0001 exercise price).
- Net proceeds: Approximately $24.5 million after fees and expenses.
- Use of proceeds: General corporate purposes, specifically R&D for expanding GraftAssure product into heart transplant rejection testing.
- Placement Agent: Lake Street Capital Markets, LLC (fees of 3.0% to 6.0% plus $125,000 expense reimbursement).
- Warrant terms: Holders subject to ownership limits (4.99% or 9.99%) with a 61-day notice period for adjustments.
Insight Molecular Diagnostics Inc. has filed an 8-K to furnish an investor presentation under Item 7.01 (Regulation FD Disclosure). The filing does not contain material non-public information but serves as a vehicle for presenting company materials to analysts and investors.
📋 Key Facts
- The company is providing an investor presentation via Exhibit 99.1.
- The disclosure is made pursuant to Item 7.01 of Form 8-K (Regulation FD).
- The information provided in the exhibit is not considered 'filed' for purposes of Section 18 liability.
Insight Molecular Diagnostics Inc. filed an 8-K to announce its financial results for the three and nine months ended September 30, 2025.
📋 Key Facts
- Report date: November 10, 2025
- Reporting period: Three and nine months ended September 30, 2025
- The filing includes a press release as Exhibit 99.1 regarding financial results.
Insight Molecular Diagnostics Inc. announced equity incentive grants to several key executives and an amendment to the employment agreement for its Chief Science Officer, Dr. Ekkehard Schütz.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- On September 28, 2025, the Board approved stock option grants to CEO Josh Riggs (400,000 shares), CFO Andrea James (235,000 shares), CSO Dr. Ekkehard Schütz (235,000 shares), and VP Accounting James Liu (18,000 shares).
- The options have an exercise price of $3.33 per share, based on the prior day's closing price.
- Options vest over a three-year period: 1/3 at the first anniversary, remainder in equal monthly installments over the following two years.
- An amendment to Dr. Schütz's employment agreement was entered into, effective September 29, 2025, changing his term from a fixed four-year period to continuing until termination under existing terms.
Insight Molecular Diagnostics Inc. announced salary increases for its President and CEO, Joshua Riggs, and Chief Financial Officer, Andrea James, effective September 15, 2025.
📋 Key Facts
- Joshua Riggs (President and CEO) base salary increased from $420,000 to $520,000, effective Sept 15, 2025.
- Andrea James (CFO) base salary increased from $341,250 to $441,250, effective Sept 15, 2025.
- The increases were approved by the Board of Directors and the Compensation Committee.
Insight Molecular Diagnostics Inc. filed an 8-K to announce its financial results for the six months ended June 30, 2025.
📋 Key Facts
- Reporting period: Six months ended June 30, 2025
- Filing date: August 11, 2025
- The filing includes a press release (Exhibit 99.1) detailing financial results.
Insight Molecular Diagnostics Inc. held its 2025 Annual Meeting of Shareholders on June 27, 2025. The company successfully passed all four proposals, including the election of directors and the ratification of their independent auditor.
📋 Key Facts
- Annual Meeting held virtually via live webcast on June 27, 2025.
- Voting power represented by 21,008,960 shares (73.46% of all common stock as of May 12, 2025 record date).
- Four director nominees elected: Joshua Riggs, Andrew Arno, Andrew J. Last, and Louis E. Silverman.
- CBIZ CPAs P.C. ratified as independent registered public accounting firm for the year ending Dec 31, 2025.
- Shareholders approved a non-binding 'Say on Pay' advisory vote regarding executive compensation for 2024.
- Approved amendment to the 2018 Equity Incentive Plan to increase authorized shares by 1.5 million (totaling 3.8 million).
Oncocyte Corp has changed its corporate name to Insight Molecular Diagnostics Inc. and is updating its Nasdaq ticker symbol from 'OCX' to 'IMDX'. The change is effective as of June 13, 2025, with the new ticker expected to trade starting June 18, 2025.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Corporate name changed from Oncocyte Corporation to Insight Molecular Diagnostics Inc. on June 13, 2025.
- Ticker symbol change: 'OCX' will cease trading and 'IMDX' will begin trading on Nasdaq before market open on June 18, 2025.
- The name change was executed via a merger of the Company’s wholly-owned subsidiary into the Company.
- No change to the company's CUSIP number.
- The change did not require shareholder approval and does not affect security holder rights.
Oncocyte Corporation issued an 8-K to announce its financial results for the three months ended March 31, 2025. The filing serves as a formal announcement of the release of quarterly earnings data.
📋 Key Facts
- Report date: May 12, 2025
- Reporting period: Three months ended March 31, 2025
- The company issued a press release (Exhibit 99.1) containing the financial results.
- Information under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
Oncocyte Corporation has terminated its relationship with Marcum LLP and engaged CBIZ CPAs P.C. as its new independent registered public accounting firm for the fiscal year ending December 31, 2025.
🚩 Red Flags
- Historical 'going concern' language in the 2023 annual report (though not noted for 2024).
- Auditor change occurring mid-cycle/transition period.
📋 Key Facts
- Termination of Marcum LLP effective April 11, 2025.
- Engagement of CBIZ CPAs P.C. approved by the Audit Committee on April 16, 2025.
- The company confirmed there were no disagreements with Marcum regarding accounting principles or auditing scope prior to termination.
- The fiscal year 2023 audit report included an explanatory paragraph regarding substantial doubt about the Company's ability to continue as a going concern.
Oncocyte Corporation issued an 8-K to announce its financial results for the three and twelve months ended December 31, 2024. The filing serves as a formal notice that the company's quarterly/annual earnings press release has been furnished.
📋 Key Facts
- Report date: March 24, 2025
- Reporting period: Three and twelve months ended December 31, 2024
- The filing includes a press release as Exhibit 99.1
- Information under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability
Oncocyte Corporation announced several executive compensation adjustments and the promotion of James Liu to Vice President Accounting, Controller, Treasurer, and Principal Accounting Officer. The changes include salary increases for the CEO, CFO, and CSO, along with significant RSU grants for top leadership.
🚩 Red Flags
- Significant equity grants to executives (totaling over $1.3M in RSU value) during a period where financial results for FY2024 are pending release.
📋 Key Facts
- CEO Joshua Riggs' annual base salary increased from $400,000 to $420,000, effective March 10, 2025.
- CFO Andrea James' annual base salary increased from $325,000 to $341,250; she also received a one-time $25,000 bonus in cash or RSUs.
- CSO Ekkehard Schüetz's annual base salary increased from $378,025 to $396,926.
- Joshua Riggs granted $600,000 in RSUs (max 200,000 shares) with a 4-year vesting schedule.
- Andrea James and Ekkehard Schüetz each granted $360,000 in RSUs (max 120,000 shares each).
- James Liu promoted to VP Accounting, Controller, Treasurer, and Principal Accounting Officer with an annual salary of $225,000.
- James Liu received a one-time grant of $60,000 in RSUs and 10,000 options.
Oncocyte Corporation announced a significant dual-track financing involving a $21.7 million PIPE (Private Investment in Public Equity) and a $7.4 million registered direct offering, totaling approximately $29.1 million in gross proceeds. The company also terminated its existing at-the-market (ATM) sales agreement with Needham & Company.
🚩 Red Flags
- Significant dilution: The issuance of over 7.5 million shares via PIPE and 3.6 million via RD represents a substantial increase in share count.
- Pre-funded warrants: These act as quasi-equity that will convert into common stock, creating further potential dilution at near-zero cost ($0.0001).
- Termination of ATM agreement: Suggests the company is moving away from smaller, incremental capital raises toward larger, concentrated dilutive events.
- Heavy reliance on private placements/direct offerings which often signal urgent need for working capital.
📋 Key Facts
- PIPE Purchase Agreement: Issuance of 7,536,708 common shares and up to 3,069,925 pre-funded warrants at $2.05 per unit/share.
- Registered Direct Offering: Sale of 3,609,755 common shares at $2.05 per share.
- Total expected gross proceeds: ~$29.1 million (before expenses).
- Pre-funded warrants have an exercise price of $0.0001 per share.
- The company entered into a Registration Rights Agreement to register the resale of these securities by March 31, 2025.
- Termination of Sales Agreement with Needham & Company (previously used for ATM offerings).
Oncocyte Corporation entered into an amendment to its office lease agreement with Induce Biologics USA, Inc. and Cushing Ventures, LLC, effective January 2, 2025. The amendment involves the termination of original extension rights in favor of a replacement lease for a third party and a structured reduction of the Company's $1,700,000 letter of credit.
🚩 Red Flags
- Termination of lease extension rights may indicate limited long-term control over current office space, though replaced by a new arrangement for Induce Biologics.
📋 Key Facts
- Effective date: January 2, 2025.
- The amendment terminates all rights to extend the Original Lease (dated Dec 23, 2019).
- The Original Lease will expire on October 31, 2027.
- A $1,700,000 Letter of Credit held by Cushing Ventures, LLC is scheduled to be reduced by $60,714.29 monthly starting July 1, 2025, provided the Company is not in default.
- The reduction in the Letter of Credit will result in a corresponding reduction in the Company's Restricted Cash on the balance sheet.
Oncocyte Corporation issued a press release announcing its financial results for the three and nine months ended September 30, 2024. This is a routine earnings announcement filing.
📋 Key Facts
- Report date: November 12, 2024
- Reporting period: Three and nine months ended September 30, 2024
- The filing includes Exhibit 99.1 containing the press release of financial results.
Oncocyte Corporation held a special meeting of stockholders on October 11, 2024, where shareholders approved the amendment and restatement of the company's 2018 Equity Incentive Plan. The approval includes an increase in shares available for equity awards and changes to award administration rules.
🚩 Red Flags
- Increase in total shares available for issuance (1.25M new shares) can lead to future dilution for existing shareholders.
📋 Key Facts
- Special Meeting held on October 11, 2024, with 64.21% of voting power represented (8,587,771 shares).
- Stockholders approved the Amended and Restated 2018 Equity Incentive Plan.
- The amendment adds 1,250,000 shares of common stock to the pool, bringing total available shares since inception to 2,300,000.
- New provisions allow the Board/committees to delegate limited authority to grant awards to executive officers.
- Elimination of 'fungible share counting' and 'share recycling' restrictions to increase flexibility in managing equity awards.
Oncocyte Corporation entered into a securities purchase agreement to conduct a private placement of 3,461,138 common shares at $2.948 per share. The transaction is expected to raise approximately $10.2 million in gross proceeds for general corporate purposes and working capital.
🚩 Red Flags
- Potential dilution for existing shareholders due to the issuance of over 3.4 million new shares.
- The use of proceeds is designated for 'working capital,' which often indicates a need to bolster immediate cash runway in micro-cap companies.
📋 Key Facts
- Private placement of 3,461,138 common shares at a price of $2.948 per share.
- Expected gross proceeds of approximately $10.2 million (before fees/expenses).
- Closing is expected on or about October 4, 2024.
- Includes a Registration Rights Agreement requiring the company to file a registration statement within 15-30 days.
- Needham & Company, LLC served as the exclusive placement agent.
Oncocyte Corporation entered into a new $7.5 million 'at-the-market' (ATM) sales agreement with Needham & Company, LLC to fund working capital and general corporate purposes. Simultaneously, the company terminated its previous ATM agreement with BTIG, LLC.
🚩 Red Flags
- Equity dilution: The company is actively seeking to raise capital through the issuance of new common stock.
- Cash runway management: Use of proceeds for 'working capital' often indicates a need for immediate liquidity to sustain operations.
📋 Key Facts
- Entered into a Sales Agreement with Needham & Company, LLC on August 9, 2024.
- The agreement allows for the sale of up to $7,500,000 in common stock via 'at-the-market' offerings.
- Sales Agent (Needham) will receive a 3.0% commission on aggregate gross proceeds.
- Proceeds are intended for working capital and general corporate purposes.
- Terminated the prior $50,000,000 ATM Sales Agreement with BTIG, LLC.
Oncocyte Corporation filed an 8-K to announce the release of its financial results for the three and six months ended June 30, 2024. The filing serves as a formal notice that earnings data has been made public via a press release.
📋 Key Facts
- Financial results were released for the periods ending June 30, 2024 (three and six months).
- The announcement was made on August 8, 2024.
- Results are contained in Exhibit 99.1.
Oncocyte Corporation announced that it has regained compliance with Nasdaq listing rules regarding board and audit committee independence. The non-compliance was triggered by the passing of director Alfred D. Kingsley on April 25, 2024.
🚩 Red Flags
- Previous non-compliance with Nasdaq listing rules regarding board and audit committee independence (Rules 5605(b)(1) and 5605(c)(2)).
📋 Key Facts
- The Company received notice from Nasdaq on July 8, 2024, confirming it regained compliance with Rules 5605(b)(1) and 5605(c)(2).
- Non-compliance was caused by the death of director Alfred D. Kingsley on April 25, 2024.
- Compliance was restored effective July 1, 2024, following the determination that Andrew Arno qualifies as an independent director/audit committee member.
- The independence determination for Andrew Arno was previously disclosed in a July 5, 2024, 8-K filing.
Oncocyte Corporation held its 2024 Annual Meeting of Shareholders on June 28, 2024. The company successfully elected four directors, ratified Marcum LLP as its independent auditor, and received non-binding approval for executive compensation.
🚩 Red Flags
- High number of Broker Non-Votes in several categories suggests potential lack of direct shareholder engagement or proxy solicitation issues, though common in micro-caps.
📋 Key Facts
- Annual Meeting held virtually on June 28, 2024.
- Voting power represented by 10,894,536 shares (81.52% of total voting power as of April 29, 2024).
- Four directors elected: Joshua Riggs, Andrew Arno, Andrew J. Last, and Louis E. Silverman.
- Marcum LLP ratified as the independent registered public accounting firm for fiscal year ending Dec 31, 2024.
- Shareholders approved 'Say on Pay' (executive compensation) on a non-binding advisory basis.
- Andrew Arno was determined to be an 'independent' director by the Board effective July 1, 2024.
Oncocyte Corporation announced the appointment of Andrea James as Chief Financial Officer and Principal Financial Officer, effective June 17, 2024. Ms. James brings significant experience from Axon Enterprise and Tesla.
📋 Key Facts
- Andrea James appointed as CFO and Principal Financial Officer effective June 17, 2024.
- James Liu will continue in the role of Senior Director, Controller & Principal Accounting Officer.
- Ms. James's base salary is set at $325,000 with a target annual cash bonus of 50% of base salary.
- Compensation includes an option to purchase 200,000 shares and a grant of 100,000 Restricted Stock Units (RSUs), subject to shareholder approval of plan amendments.
- Ms. James previously held senior leadership roles at Axon Enterprise, including SVP of Corporate Strategy & Investor Relations.
Oncocyte Corporation announced salary increases for its President and CEO, Senior Director/Controller, and Chief Science Officer. The changes were approved by the Board on May 30, 2024, with an effective date of May 20, 2024.
🚩 Red Flags
- None identified in this specific filing.
📋 Key Facts
- Joshua Riggs (President & CEO) salary increased from $360,000 to $400,000.
- James Liu (Senior Director, Controller & Principal Accounting Officer, and Interim PFO) salary increased from $200,000 to $207,000.
- Ekkehard Schütz, M.D., Ph.D. (Chief Science Officer) salary increased from $351,525 to $378,025.
- Salary increases were effective as of May 20, 2024.
Oncocyte Corporation entered into a new employment agreement with its Chief Science Officer, Ekkehard Schütz, M.D., Ph.D., effective May 20, 2024. This agreement replaces his previous service agreement with the company's German subsidiary.
🚩 Red Flags
- None identified in this specific filing.
📋 Key Facts
- Effective Date of new agreement: May 20, 2024.
- Dr. Ekkehard Schütz appointed/retained as Chief Science Officer.
- Annual Base Salary: $351,525.20.
- Annual Cash Bonus eligibility: 50% of Base Salary.
- Agreement term: Until termination or four years from the Effective Date.
- The agreement replaces a previous Managing Director Service Agreement with Chronix Biomedical GmbH (a wholly owned German subsidiary).
Oncocyte Corporation issued a press release announcing its financial results for the three months ended March 31, 2024. This is a standard quarterly earnings announcement filing.
📋 Key Facts
- Report date: May 15, 2024
- Reporting period: Three months ended March 31, 2024
- The filing includes Exhibit 99.1 containing the press release of financial results.
Oncocyte Corporation entered into a securities purchase agreement for a private placement of approximately 5.08 million common shares and pre-funded warrants, expected to raise $15.8 million in gross proceeds. A significant portion ($5 million) is earmarked to redeem Series A Redeemable Convertible Preferred Stock due on April 15, 2024.
🚩 Red Flags
- Significant dilution: Issuance of over 5 million shares in a private placement.
- Urgent capital need: Proceeds are required to meet a redemption obligation for Series A Preferred Stock due on April 15, 2024 (only days after the agreement date).
- Pre-funded warrants: These often act as delayed equity issuance and can lead to further dilution upon exercise.
📋 Key Facts
- Private placement of 5,077,387 Common Shares and 342,888 Pre-Funded Warrants.
- Issuance price: $2.9164 per share/warrant (pre-funded).
- Expected gross proceeds: ~$15.8 million before fees.
- $5 million of proceeds to be used for redemption of Series A Redeemable Convertible Preferred Stock on April 15, 2024.
- Registration rights agreement signed; company must file registration statement within 30 days and aim for effectiveness within 60-75 days.
- Needham & Company, LLC served as exclusive placement agent.
Oncocyte Corporation entered into a 10-year Collaboration Agreement with Bio-Rad Laboratories, Inc. to develop and commercialize transplant monitoring assays using Bio-Rad's ddPCR technology.
🚩 Red Flags
- Royalty obligations to Bio-Rad may impact gross margins on RUO assays.
- Dependency on Bio-Rad's ddPCR platform for product commercialization.
📋 Key Facts
- Collaboration covers both Research Use Only (RUO) Assays and In Vitro Diagnostic (IVD) Kits.
- The agreement has a 10-year term unless terminated early.
- Oncocyte will manufacture/supply RUO assays; Bio-Rad will supply ddPCR instruments and reagents.
- Joint co-promotion/co-marketing of RUO Assays in the US and Germany.
- Bio-Rad has an option for exclusive worldwide promotion/sale of IVD Kits, which includes a potential equity investment (purchase of common stock at market price).
- Oncocyte will pay Bio-Rad a single-digit royalty on net sales of RUO Assays in the Territory.
Oncocyte Corporation filed this 8-K to disclose material information regarding its VitaGraft Kidney product via a social media post on LinkedIn. This is a Regulation FD disclosure intended to ensure all investors have access to the same material information simultaneously.
📋 Key Facts
- The filing relates to an announcement made on January 22, 2024, regarding the VitaGraft Kidney product.
- The primary source of the material information is a LinkedIn post (Exhibit 99.1).
- The company utilizes social media (LinkedIn, X, Facebook) as official channels for communicating material information to the public.